Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bliss GVS PharmaBOM:506197 +4.15%58 Return-on-Tangible-Asset is 13.50% as of Jun. 2026, which is 103% above its 10-year median of 6.66. GuruFocus rates BOM:506197 with a GF Score™ of 58/100 and a GF Value™ of ₹170.72 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Bliss GVS Pharma ranks better than 76.49% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bliss GVS Pharma's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹2,004 Mil. Bliss GVS Pharma's average total tangible assets for the quarter that ended in Jun. 2026 was ₹14,845 Mil. Therefore, Bliss GVS Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 13.50%.
The historical rank and industry rank for Bliss GVS Pharma's Return-on-Tangible-Asset or its related term are showing as below:
BOM:506197'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.39 Med: 6.66 Max: 14.18
Current: 9.8
During the past 13 years, Bliss GVS Pharma's highest Return-on-Tangible-Asset was 14.18%. The lowest was 1.39%. And the median was 6.66%.
BOM:506197's Return-on-Tangible-Asset is ranked better than 76.49% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.795
vs BOM:506197: 9.80
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bliss GVS Pharma Return-on-Tangible-Asset Related Terms
Bliss GVS Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:506197 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.50% mean?
Bliss GVS Pharma (BOM:506197) has a Return-on-Tangible-Asset of 13.50% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bliss GVS Pharma and its competitors. This is 103% above median its historical median of 6.66. Over the past decade, Bliss GVS Pharma's Return-on-Tangible-Asset has ranged from 1.39 to 14.18. According to the industry distribution chart, Bliss GVS Pharma ranks #237 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Bliss GVS Pharma's Return-on-Tangible-Asset too high?
Bliss GVS Pharma's current Return-on-Tangible-Asset of 13.50% is 103% above median its 10-year median of 6.66. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 14.18. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.80. Bliss GVS Pharma's value of 13.50% is 383% above this industry median. Based on the distribution chart, Bliss GVS Pharma ranks #237 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bliss GVS Pharma has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bliss GVS Pharma ranks #237 out of 1008 companies for Return-on-Tangible-Asset. This places Bliss GVS Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.80. Bliss GVS Pharma's value of 13.50% is 383% above this benchmark. Historically, Bliss GVS Pharma's own Return-on-Tangible-Asset has ranged from 1.39 to 14.18 over the past decade. While the company's 10-year median is 6.66 vs. the industry median of 2.80, Bliss GVS Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.80, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bliss GVS Pharma's current Return-on-Tangible-Asset of 13.50% is 383% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bliss GVS Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bliss GVS Pharma's current Return-on-Tangible-Asset is 13.50%, which is 103% above median its own 10-year median of 6.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹170.72, compared to a current price of ₹696.45 — trading 307.9% above its estimated fair value. The current Return-on-Tangible-Asset is 13.50%, which is 103% above median its 10-year median of 6.66 and 383% above the Drug Manufacturers industry median of 2.80. Bliss GVS Pharma's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current Return-on-Tangible-Asset is 13.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹696.45 is trading 307.9% above its estimated GF Value™ of ₹170.72.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
Return-on-Tangible-Asset: 13.50% (103% above median its 10-year median of 6.66)
GF Value™: ₹170.72 vs. price of ₹696.45 (307.9% above fair value)
Industry Position: 383% above the Drug Manufacturers median (#237 of 1008)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
58GF Score
Get the complete analysis for BOM:506197
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
